Last reviewed · How we verify
SC CLS-TA
SC CLS-TA is a Small molecule drug developed by Clearside Biomedical, Inc.. It is currently in Phase 2 development. Also known as: Triamcinolone Acetonide.
SC CLS-TA is a small molecule intervention used in a study for Diabetic Macular Edema, Macular Edema, and Retinal Vein Occlusion. It is being compared to IVT aflibercept and sham SC in a randomized, double-masked, controlled study.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SC CLS-TA |
|---|---|
| Also known as | Triamcinolone Acetonide |
| Sponsor | Clearside Biomedical, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema (PHASE1, PHASE2)
- Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema (PHASE2)
- Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO (PHASE3)
- Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC CLS-TA CI brief — competitive landscape report
- SC CLS-TA updates RSS · CI watch RSS
- Clearside Biomedical, Inc. portfolio CI
Frequently asked questions about SC CLS-TA
What is SC CLS-TA?
Who makes SC CLS-TA?
Is SC CLS-TA also known as anything else?
What development phase is SC CLS-TA in?
Related
- Manufacturer: Clearside Biomedical, Inc. — full pipeline
- Also known as: Triamcinolone Acetonide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing